Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer

克拉斯 免疫检查点 结直肠癌 癌症研究 癌症 免疫疗法 封锁 微卫星不稳定性 免疫系统 医学 免疫学 生物 内科学 基因 遗传学 等位基因 受体 微卫星
作者
Kay Hänggi,Brian Ruffell
出处
期刊:Cancer Cell [Cell Press]
卷期号:35 (4): 535-537 被引量:37
标识
DOI:10.1016/j.ccell.2019.03.008
摘要

In this issue of Cancer Cell, Liao et al. demonstrate that oncogenic KRAS drives an immune suppressive program in colorectal cancer by repressing IRF2 expression, which leads to downregulation of interferon responsive genes, enhanced expression of CXCL3 and recruitment of suppressive myeloid cells, and subsequent resistance to immune checkpoint blockade. In this issue of Cancer Cell, Liao et al. demonstrate that oncogenic KRAS drives an immune suppressive program in colorectal cancer by repressing IRF2 expression, which leads to downregulation of interferon responsive genes, enhanced expression of CXCL3 and recruitment of suppressive myeloid cells, and subsequent resistance to immune checkpoint blockade. The 5-year survival rate for patients with metastatic colorectal cancer (CRC) is a mere 12%. Immune checkpoint blockade with anti-programmed death (PD)-1 has recently been approved for use in patients with microsatellite instability-high (MSI-H) CRC, with an objective response rate of around 40%; however, efficacy is absent in microsatellite-stable (MSS) disease, which represents the majority of CRCs (Overman et al., 2018Overman M.J. Ernstoff M.S. Morse M.A. Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management.Am. Soc. Clin. Oncol. Educ. Book. 2018; : 239-247Crossref PubMed Scopus (74) Google Scholar). In addition to inactivating mutations in APC and TRP53, oncogenic KRAS mutations (usually G12D) are frequent drivers of aggressive disease in MSS CRC (Overman et al., 2018Overman M.J. Ernstoff M.S. Morse M.A. Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management.Am. Soc. Clin. Oncol. Educ. Book. 2018; : 239-247Crossref PubMed Scopus (74) Google Scholar). Although KRAS mutations do not predict response to anti-PD-1, they are associated with reduced T cell infiltration, hinting that downstream pathways could regulate immunotherapy and may become relevant as additional combinations of immune checkpoint inhibitors enter the clinic. In this issue of Cancer Cell, Liao et al., 2019Liao W. Overman M.J. Boutin A.T. Shang X. Zhao D. Dey P. Li J. Wang G. Lan Z. Li J. et al.KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer.Cancer Cell. 2019; 35 (this issue): 559-572Abstract Full Text Full Text PDF PubMed Scopus (250) Google Scholar demonstrate that KrasG12D suppresses expression of interferon regulatory factor 2 (IRF2), a negative regulator of the CXCL3 chemokine expression (Figure 1). This leads to enhanced recruitment of myeloid-derived suppressor cells (MDSCs) and restricted T cell accumulation, a resistance mechanism that limits response to anti-PD-1 therapy. To explore the role of KRASG12D in CRC, the authors utilize an advanced murine model employing tamoxifen-inducible cre recombinase under control of the Villin promoter, floxed alleles of Apc and Trp53, and doxycycline-inducible expression of KrasG12D (designated iKAP). This model has a mesenchymal phenotype and activated TGF-β signaling (Boutin et al., 2017Boutin A.T. Liao W.-T. Wang M. Hwang S.S. Karpinets T.V. Cheung H. Chu G.C. Jiang S. Hu J. Chang K. et al.Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.Genes Dev. 2017; 31: 370-382Crossref PubMed Scopus (101) Google Scholar) and reflects MSS disease of the CMS4 subtype (Guinney et al., 2015Guinney J. Dienstmann R. Wang X. de Reyniès A. Schlicker A. Soneson C. Marisa L. Roepman P. Nyamundanda G. Angelino P. et al.The consensus molecular subtypes of colorectal cancer.Nat. Med. 2015; 21: 1350-1356Crossref PubMed Scopus (2688) Google Scholar). To determine whether the model also recapitulated the poor T cell infiltration seen in KRASG12D human tumors, the authors performed cytometry by time of flight (CyTOF) to characterize the immune landscape. As expected, KrasG12D tumors displayed a reduction in CD4+ and CD8+ T cell infiltration, as compared to tumors harboring only null alleles of Apc and Trp53 (designated iAP). The authors also noted a substantial increase in CD11b+Ly6G+ polymorphonuclear (PMN) cells with the capacity to block T cell proliferation in a classic immunosuppressive assay, marking these as PMN-MDSCs. Critically, this infiltration was not a byproduct of tumor development in the presence of KrasG12D, as removal of doxycycline reversed this immune phenotype. Thus, expression of oncogenic KRAS drives the creation of an immunosuppressive tumor microenvironment in CRC. Ingenuity pathway analysis of RNA-seq profiles revealed a strong correlation between KrasG12D expression and downregulation of an interferon (IFN) response. This was true in both whole tumors and in cell lines derived from the murine model, suggesting an intrinsic ability of KRASG12D expression to suppress expression of IFN responsive genes. The authors then compared significant changes in gene expression in their murine data with genomic deletions in human CRC that were mutually exclusive with KRAS mutations, and integrating these datasets led to a single gene of interest, IRF2. To determine whether reduced IRF2 levels in KrasG12D tumors was a driver of the observed phenotype, IRF2 was overexpressed in iKAP cell lines, which reversed the IFN signature, including genes related to immunity and antigen presentation. While a reduced IFN response might explain lower T cell infiltration, it did not explain increased recruitment of PMN-MDSC in iKAP tumors. The authors therefore evaluated migration of MDSCs in response to conditioned media from iKAP cell lines, compared to those overexpressing IRF2. Conversely, IRF2 was knocked down in the KRAS wild-type MC38 cell line. In each case, expression of IRF2 was inversely associated with MDSC migration. Gene expression for cytokines and chemokines was then compared with IRF2 ChIP-seq, leading to the identification of CXCL3. IRF2 suppression of Cxcl3 was confirmed by real-time RT-PCR, and Cxcl3 was expressed at higher levels than other neutrophil chemoattractants. Significantly decreased in vitro migration was also found following neutralization of CXCL3 or inhibition of its receptor CXCR2 with the inhibitor SX-682 (Lu et al., 2017Lu X. Horner J.W. Paul E. Shang X. Troncoso P. Deng P. Jiang S. Chang Q. Spring D.J. Sharma P. et al.Effective combinatorial immunotherapy for castration-resistant prostate cancer.Nature. 2017; 543: 728-732Crossref PubMed Scopus (333) Google Scholar). Most importantly, administration of SX-682 to iKAP, but not iAP mice, dramatically reduced PMN-MDSC recruitment, while increasing recruitment of T cells into tumors, which was similar to the phenotype observed following MDSC depletion. Does PMN-MDSC recruitment lead to changes in tumor growth? iKAP tumors were resistant to anti-PD-1 therapy, and SX-682 alone was without efficacy; however, the combination more than doubled survival over the course of the experiment. This efficacy correlated with increased CD8+ T cell and reduced regulatory T cell (Treg) infiltration. The authors also found that expression of KRASG12D in the MC38 cell line led to anti-PD-1 resistance, a phenotype that was reversed by IRF2 overexpression or treatment with SX-682. Cumulatively, these data support the authors' model in which oncogenic KRAS inhibits expression of IRF2, leading to production of CXCL3, recruitment of CXCR2+ PMN-MDSCs, and suppression of the anti-tumor T cell response. Finally, the authors provide strong correlative data that the identified KRAS-IRF2-IFN axis is relevant in human CRC. This includes KRAS mutant tumors showing lower expression of IRF2, as well as a significantly diminished IFN gene signature. IRF2 expression in KRAS wild-type and mutant patient samples was heterogeneous, which could be due to spatial or expression level heterogeneity of KRAS or indicative of additional regulatory mechanisms. While this limits the utility of KRAS mutational status as a predictive biomarker in immunotherapy, it hints that IRF2 could prove more informative. Impressively, Liao et al. evaluated IRF2 expression in pre-treatment biopsies of 14 MSI CRCs and found that 5/7 patients with low IRF2-expressing CRC were non-responders to anti-PD-1 while 7/7 patients with high IRF2-expressing CRC had a complete response, partial response, or stable disease. Despite the small sample size, this supports further exploration of IRF2 as a biomarker and lends credence to this pathway being an important regulator of the immune system in CRC. Whether this occurs through CXCL3 expression and recruitment of MDSCs in patients requires further validation, as the correlation of CXCL3 with IRF2 expression or KRAS mutation status was relatively weak. However, putative PMN-MDSCs are observed in human CRC (Condamine et al., 2016Condamine T. Dominguez G.A. Youn J.-I. Kossenkov A.V. Mony S. Alicea-Torres K. Tcyganov E. Hashimoto A. Nefedova Y. Lin C. et al.Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.Sci. Immunol. 2016; 1: aaf8943Crossref PubMed Scopus (435) Google Scholar) and appear to regulate response to immune checkpoint blockade in other cancers (Davis et al., 2017Davis R.J. Moore E.C. Clavijo P.E. Friedman J. Cash H. Chen Z. Silvin C. Van Waes C. Allen C. Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kδ/γ.Cancer Res. 2017; 77: 2607-2619Crossref PubMed Scopus (140) Google Scholar, Weber and Fottner, 2018Weber M.M. Fottner C. Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia.Oncol. Res. Treat. 2018; 41: 306-312Crossref PubMed Scopus (63) Google Scholar) With the success of immunotherapy, the fields of cancer biology and cancer immunology are finally becoming integrated, and the impact of proto-oncogene and tumor suppressor mutations on the microenvironment and immune response is now being elucidated (Wellenstein and de Visser, 2018Wellenstein M.D. de Visser K.E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape.Immunity. 2018; 48: 399-416Abstract Full Text Full Text PDF PubMed Scopus (322) Google Scholar). Oncogenic KRAS has been found to promote MDSC recruitment via induced expression of granulocyte-macrophage colony stimulating factor (GM-CSF) and CXCL1/2 in murine pancreatic and lung cancer, respectively, and to even promote PD-L1 expression in lung cancer (Wellenstein and de Visser, 2018Wellenstein M.D. de Visser K.E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape.Immunity. 2018; 48: 399-416Abstract Full Text Full Text PDF PubMed Scopus (322) Google Scholar). Only increased PD-L1 expression was observed in this study, and whether this heterogeneity in resistance mechanisms is due to tissue- or mutation-specific factors remains unknown. It will certainly be interesting to determine whether the KRAS-IRF2 axis translates into other cancer types driven by oncogenic KRAS. Liao et al., 2019Liao W. Overman M.J. Boutin A.T. Shang X. Zhao D. Dey P. Li J. Wang G. Lan Z. Li J. et al.KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer.Cancer Cell. 2019; 35 (this issue): 559-572Abstract Full Text Full Text PDF PubMed Scopus (250) Google Scholar observe that inhibiting PMN-MDSC recruitment led to an opposing increase in Treg recruitment, identifying an adaptive resistance mechanism that has also been problematic with other myeloid targeted therapies (DeNardo and Ruffell, 2019DeNardo D.G. Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy.Nat. Rev. Immunol. 2019; Crossref PubMed Scopus (837) Google Scholar). Fortunately, Treg recruitment was reversed by anti-PD-1 therapy in this model, raising hope for ongoing clinical trials combining SX-692 and anti-PD-1 in melanoma (NCT03161431). Nevertheless, targeting CXCR2 bypasses activation of the IFN response in tumor cells, which could potentially limit therapeutic efficacy. Determining the mechanism by which oncogenic KRAS suppresses IRF2 expression could therefore open up new avenues for therapeutic intervention. K.H. is supported by a Swiss National Science Foundation postdoc mobility fellowship (P400PM_183881). B.R. has a courtesy faculty appointment at the University of South Florida, Tampa, FL 33620. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal CancerLiao et al.Cancer CellMarch 21, 2019In BriefLiao et al. show that oncogenic KRAS represses IRF2 expression leading to high expression of CXCL3, which binds CXCR2 on MDSCs to promote their migration into the tumor microenvironment. Enforced IRF2 expression or CXCR2 blockade overcomes resistance of tumors expressing oncogenic KRAS to anti-PD-1 therapy. Full-Text PDF Open Archive
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft的应助被刘婉敏采纳,获得10
刚刚
MMMMathilda23发布了新的文献求助10
1秒前
Ava的应助被周周不喝粥采纳,获得10
1秒前
chen发布了新的文献求助10
2秒前
LH大王发布了新的文献求助10
2秒前
3秒前
小二郎的应助被高远亮采纳,获得10
3秒前
科研通AI6.2的应助被欧皇蘭采纳,获得10
3秒前
4秒前
5秒前
盒子发布了新的文献求助10
5秒前
5秒前
大耳朵图图完成签到 ,获得积分10
5秒前
爱听歌钥匙完成签到,获得积分10
5秒前
5秒前
FashionBoy的应助被懿生采纳,获得10
6秒前
九三发布了新的文献求助10
6秒前
7秒前
JIEJIE完成签到,获得积分10
7秒前
乐乐的应助被phoebe采纳,获得10
8秒前
电风扇关注了科研通微信公众号
10秒前
香蕉觅云的应助被高天采纳,获得10
10秒前
xstar发布了新的文献求助20
10秒前
10秒前
SYX发布了新的文献求助10
10秒前
11秒前
11秒前
领导范儿的应助被xin采纳,获得10
12秒前
行者发布了新的文献求助10
13秒前
13秒前
晶晶完成签到 ,获得积分10
13秒前
13秒前
初景发布了新的文献求助10
14秒前
tt完成签到,获得积分10
14秒前
14秒前
天天快乐的应助被盒子采纳,获得10
15秒前
烟花的应助被卡乐瑞咩吹可采纳,获得10
16秒前
多多完成签到,获得积分10
16秒前
九三完成签到,获得积分10
16秒前
Tracer完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178375
求助须知:如何正确求助?哪些是违规求助? 9569182
关于积分的说明 21802781
捐赠科研通 7773247
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556793
邀请新用户注册赠送积分活动 2478346